BioNTech to Initiate 15 Phase 3 Trials in 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 12 2026
0mins
Should l Buy BMY?
BioNTech (BNTX) will continue to execute its strategy in 2026 towards becoming a multi-product oncology company. Its diversified oncology pipeline comprises late-stage candidates spanning immunomodulators, antibody drug conjugates, and mRNA cancer immunotherapies. BioNTech is developing several assets with pan-tumor potential, including novel-novel combination approaches, with the aim of addressing the full continuum from early- to late-stage disease across selected tumor types. Late-Stage Acceleration: BioNTech is focused on advancing its late-stage oncology pipeline towards potential launches. Within the past two years, the company has more than doubled the number of Phase 2 and 3 oncology trials across key modalities with now more than 25 Phase 2 or 3 trials ongoing. In 2026, BioNTech plans to initiate six additional Phase 3 clinical trials, bringing the total number of anticipated Phase 3 clinical trials to 15, and expects seven late-stage data readouts. The clinical trials and resulting data will inform regulatory and launch plans. Combination Therapy Momentum: BioNTech has more than ten novel-novel combination clinical trials in its pipeline with multiple data updates expected in 2026. These trials explore pumitamig, which is being partnered with Bristol Myers Squibb (BMY), in combination with other investigational immunomodulators, ADCs, and mRNA cancer immunotherapies and will inform the dose selection and explore anti-tumor activity in multiple tumors for later-stage development. From Modalities to Disease Area: With the maturation of the oncology pipeline, BioNTech will focus on specific disease areas across major cancer types, including lung, breast, gynecologic, gastrointestinal, and genitourinary cancers.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BMY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BMY
Wall Street analysts forecast BMY stock price to fall
20 Analyst Rating
8 Buy
11 Hold
1 Sell
Moderate Buy
Current: 58.960
Low
37.00
Averages
55.86
High
68.00
Current: 58.960
Low
37.00
Averages
55.86
High
68.00
About BMY
Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Opdualag (nivolumab and relatlimab-rmbw), Breyanzi (lisocabtagene maraleucel), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), and Sotyktu (deucravacitinib). Its other growth products include Onureg, Inrebic, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension). Opdivo (nivolumab) is a fully human monoclonal antibody that binds to the PD-1 on T and NKT cells.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
CNBC Investing Club April Meeting Highlights
- Market Rebound Analysis: The S&P 500 index reached a record high in April, marking a significant recovery from the Iran war sell-off, indicating a renewed focus on company fundamentals despite the ongoing conflict, which underscores the importance of investor calmness.
- Nike Investment Reflection: Despite insider buying signals prompting us to increase our stake in Nike last December, we are now skeptical about CEO Elliott Hill's ability to turn the company around, and if next quarter's performance is disappointing, we will consider exiting.
- Amazon Cloud Business Recovery: Amazon's stock rebound highlights the importance of patience, as the market is gradually recognizing the strength of its AWS cloud division and online retail business, which are expected to continue growing in the future.
- Nvidia Market Leadership: Nvidia's leading position in the AI chip sector is paying off, and despite competitive pressures, its advantage in computing power positions it well to maintain market leadership going forward.
See More
Stock Market Surge: Nasdaq and S&P 500 Reach Record Highs
- Market Rally: Since March 30, the S&P 500 and Nasdaq have surged by 10.7% and 15.5%, respectively, reaching record highs, indicating a significant improvement in investor sentiment driven by hopes for a resolution to the Middle East conflict.
- Oil Price Decline: U.S. oil prices have dropped approximately 18% from their war peak of nearly $113 per barrel on April 6, alleviating inflationary pressures and supporting the stock market rebound, which further bolsters investor confidence.
- Top Performing Stocks: Stocks like Broadcom, Corning, Meta, and Amazon have excelled, rising 35.2%, 30.9%, 25.2%, and 23.7%, respectively, reflecting strong demand in the tech and infrastructure sectors that has propelled overall portfolio performance.
- Underperforming Stocks: Conversely, Nike, Salesforce, Johnson & Johnson, and Costco have seen declines, with Nike dropping 11.3% due to disappointing earnings, highlighting market concerns about its recovery, while Salesforce fell 4% amid worries about the impact of generative AI on its business model.
See More
Analysis of Investment Prospects in Healthcare Stocks
- Animal Health Leader: Zoetis has faced challenges over the past two years, including increased competition and scrutiny over drug side effects; however, its strong market position and the potential market for untreated dogs make it attractive for long-term investors, with expectations to continue launching new products to meet rising pet spending.
- New Drug Development Potential: BioNTech has underperformed in the coronavirus vaccine market, but its impressive pipeline with over 25 clinical trials in oncology, particularly the promising BNT327 developed with Bristol Myers Squibb, could set new standards of care across multiple indications, with significant clinical and regulatory progress expected over the next five years.
- Gene Editing Risks: Intellia Therapeutics' lonvo-z and nex-z are undergoing phase 3 studies but face uncertainty; despite the FDA lifting the hold on clinical trials, the high costs and complexities of gene editing treatments make steady revenue generation unlikely in the coming years, presenting substantial investment risks.
- Dividend Appeal: Zoetis has increased its dividends by 458% over the past decade, making it a top choice for income-seeking investors, reflecting its long-term investment value in the animal health market despite facing short-term challenges.
See More
Strong Performance Fuels Promising Growth Outlook
- Significant Revenue Growth: Johnson & Johnson reported a 9.9% year-over-year revenue increase in Q1, reaching $24.06 billion, surpassing the market expectation of $23.63 billion, which underscores the company's robust performance in pharmaceuticals and medical technology, further solidifying its market position.
- Adjusted EPS Exceeds Expectations: The adjusted earnings per share for the first quarter stood at $2.70, exceeding the anticipated $2.66, reflecting effective management in cost control and profitability, which enhances investor confidence.
- Strong New Drug Sales: Sales of the blood cancer therapy Darzalex rose 22.5% year-over-year to $3.96 billion, exceeding market expectations, while Tremfya sales surged 68% to $1.61 billion, showcasing Johnson & Johnson's competitiveness and market demand in innovative pharmaceuticals.
- Optimistic Future Growth Guidance: Johnson & Johnson raised its full-year guidance, projecting revenue growth between 5.9% and 6.9%, with adjusted EPS expectations increased to a range of $11.45 to $11.65, indicating the company's confidence in future performance and positive market outlook.
See More
Fed Likely to Treat Inflation as One-Off Factors, Says Cramer
- Rate Impact on Market: Jim Cramer highlights that despite escalating geopolitical tensions, the S&P 500 has recently rebounded to within 1.5% of its all-time high due to sustained low interest rates, indicating a strong market resilience.
- Oil Prices and Inflation: Cramer argues that while oil prices have surged due to supply disruptions in the Strait of Hormuz, their broader economic impact may be less pronounced than in past energy shocks, as modern vehicles are more fuel-efficient and natural gas remains relatively cheap domestically.
- Fed Policy Outlook: Cramer predicts that with interest rates stabilizing, the Fed is unlikely to raise short-term rates and may even consider rate cuts, which would further support stock valuations and investor confidence.
- Market Resilience: Cramer emphasizes that the market's ability to overlook geopolitical events and focus on fundamentals, particularly interest rates, is crucial, as evidenced by strong performances from software stocks like Salesforce and Microsoft, contrasting with lagging energy stocks.
See More
Market Resilience Driven by Interest Rates Amid Geopolitical Tensions
- Interest Rate Impact: Cramer highlights that despite escalating geopolitical tensions, low interest rates are the key driver behind the stock market's rebound, with the S&P 500 rising back to within 1.5% of its all-time high, even amid surging oil prices.
- Oil Prices and Inflation: While oil prices have surged due to supply disruptions in the Strait of Hormuz, Cramer argues that their broader economic impact is less pronounced than in past energy shocks, thanks to improved vehicle fuel efficiency and lower domestic natural gas prices, which mitigate inflationary pressures.
- Fed Policy Outlook: Cramer notes that as interest rates have rolled over, the new Federal Reserve chair may not raise short-term rates and could even consider rate cuts, further supporting high stock valuations in the market.
- Focus on Fundamentals: Cramer emphasizes that investors should concentrate on the impact of interest rates on stock prices rather than geopolitical events, as evidenced by Monday's trading where beaten-down software stocks like Salesforce and Microsoft outperformed the lagging energy sector.
See More
CNBC Investing Club April Meeting Highlights
- Market Rebound Analysis: The S&P 500 index reached a record high in April, marking a significant recovery from the Iran war sell-off, indicating a renewed focus on company fundamentals despite the ongoing conflict, which underscores the importance of investor calmness.
- Nike Investment Reflection: Despite insider buying signals prompting us to increase our stake in Nike last December, we are now skeptical about CEO Elliott Hill's ability to turn the company around, and if next quarter's performance is disappointing, we will consider exiting.
- Amazon Cloud Business Recovery: Amazon's stock rebound highlights the importance of patience, as the market is gradually recognizing the strength of its AWS cloud division and online retail business, which are expected to continue growing in the future.
- Nvidia Market Leadership: Nvidia's leading position in the AI chip sector is paying off, and despite competitive pressures, its advantage in computing power positions it well to maintain market leadership going forward.
See More
Stock Market Surge: Nasdaq and S&P 500 Reach Record Highs
- Market Rally: Since March 30, the S&P 500 and Nasdaq have surged by 10.7% and 15.5%, respectively, reaching record highs, indicating a significant improvement in investor sentiment driven by hopes for a resolution to the Middle East conflict.
- Oil Price Decline: U.S. oil prices have dropped approximately 18% from their war peak of nearly $113 per barrel on April 6, alleviating inflationary pressures and supporting the stock market rebound, which further bolsters investor confidence.
- Top Performing Stocks: Stocks like Broadcom, Corning, Meta, and Amazon have excelled, rising 35.2%, 30.9%, 25.2%, and 23.7%, respectively, reflecting strong demand in the tech and infrastructure sectors that has propelled overall portfolio performance.
- Underperforming Stocks: Conversely, Nike, Salesforce, Johnson & Johnson, and Costco have seen declines, with Nike dropping 11.3% due to disappointing earnings, highlighting market concerns about its recovery, while Salesforce fell 4% amid worries about the impact of generative AI on its business model.
See More
Analysis of Investment Prospects in Healthcare Stocks
- Animal Health Leader: Zoetis has faced challenges over the past two years, including increased competition and scrutiny over drug side effects; however, its strong market position and the potential market for untreated dogs make it attractive for long-term investors, with expectations to continue launching new products to meet rising pet spending.
- New Drug Development Potential: BioNTech has underperformed in the coronavirus vaccine market, but its impressive pipeline with over 25 clinical trials in oncology, particularly the promising BNT327 developed with Bristol Myers Squibb, could set new standards of care across multiple indications, with significant clinical and regulatory progress expected over the next five years.
- Gene Editing Risks: Intellia Therapeutics' lonvo-z and nex-z are undergoing phase 3 studies but face uncertainty; despite the FDA lifting the hold on clinical trials, the high costs and complexities of gene editing treatments make steady revenue generation unlikely in the coming years, presenting substantial investment risks.
- Dividend Appeal: Zoetis has increased its dividends by 458% over the past decade, making it a top choice for income-seeking investors, reflecting its long-term investment value in the animal health market despite facing short-term challenges.
See More
Strong Performance Fuels Promising Growth Outlook
- Significant Revenue Growth: Johnson & Johnson reported a 9.9% year-over-year revenue increase in Q1, reaching $24.06 billion, surpassing the market expectation of $23.63 billion, which underscores the company's robust performance in pharmaceuticals and medical technology, further solidifying its market position.
- Adjusted EPS Exceeds Expectations: The adjusted earnings per share for the first quarter stood at $2.70, exceeding the anticipated $2.66, reflecting effective management in cost control and profitability, which enhances investor confidence.
- Strong New Drug Sales: Sales of the blood cancer therapy Darzalex rose 22.5% year-over-year to $3.96 billion, exceeding market expectations, while Tremfya sales surged 68% to $1.61 billion, showcasing Johnson & Johnson's competitiveness and market demand in innovative pharmaceuticals.
- Optimistic Future Growth Guidance: Johnson & Johnson raised its full-year guidance, projecting revenue growth between 5.9% and 6.9%, with adjusted EPS expectations increased to a range of $11.45 to $11.65, indicating the company's confidence in future performance and positive market outlook.
See More
Fed Likely to Treat Inflation as One-Off Factors, Says Cramer
- Rate Impact on Market: Jim Cramer highlights that despite escalating geopolitical tensions, the S&P 500 has recently rebounded to within 1.5% of its all-time high due to sustained low interest rates, indicating a strong market resilience.
- Oil Prices and Inflation: Cramer argues that while oil prices have surged due to supply disruptions in the Strait of Hormuz, their broader economic impact may be less pronounced than in past energy shocks, as modern vehicles are more fuel-efficient and natural gas remains relatively cheap domestically.
- Fed Policy Outlook: Cramer predicts that with interest rates stabilizing, the Fed is unlikely to raise short-term rates and may even consider rate cuts, which would further support stock valuations and investor confidence.
- Market Resilience: Cramer emphasizes that the market's ability to overlook geopolitical events and focus on fundamentals, particularly interest rates, is crucial, as evidenced by strong performances from software stocks like Salesforce and Microsoft, contrasting with lagging energy stocks.
See More
Market Resilience Driven by Interest Rates Amid Geopolitical Tensions
- Interest Rate Impact: Cramer highlights that despite escalating geopolitical tensions, low interest rates are the key driver behind the stock market's rebound, with the S&P 500 rising back to within 1.5% of its all-time high, even amid surging oil prices.
- Oil Prices and Inflation: While oil prices have surged due to supply disruptions in the Strait of Hormuz, Cramer argues that their broader economic impact is less pronounced than in past energy shocks, thanks to improved vehicle fuel efficiency and lower domestic natural gas prices, which mitigate inflationary pressures.
- Fed Policy Outlook: Cramer notes that as interest rates have rolled over, the new Federal Reserve chair may not raise short-term rates and could even consider rate cuts, further supporting high stock valuations in the market.
- Focus on Fundamentals: Cramer emphasizes that investors should concentrate on the impact of interest rates on stock prices rather than geopolitical events, as evidenced by Monday's trading where beaten-down software stocks like Salesforce and Microsoft outperformed the lagging energy sector.
See More
